• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

估计美国大流行期间疫苗接种运动后的 COVID-19 感染、住院和死亡人数。

Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic.

机构信息

Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada.

Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut.

出版信息

JAMA Netw Open. 2022 Jan 4;5(1):e2142725. doi: 10.1001/jamanetworkopen.2021.42725.

DOI:10.1001/jamanetworkopen.2021.42725
PMID:35015067
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8753510/
Abstract

This decision analytic modeling study uses a simulation model to evaluate the association of US COVID-19 vaccination campaigns with infections, hospitalizations, and deaths.

摘要

本决策分析建模研究使用模拟模型评估了美国 COVID-19 疫苗接种活动与感染、住院和死亡之间的关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df36/8753510/aeac0e51382d/jamanetwopen-e2142725-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df36/8753510/d747575d748d/jamanetwopen-e2142725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df36/8753510/aeac0e51382d/jamanetwopen-e2142725-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df36/8753510/d747575d748d/jamanetwopen-e2142725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df36/8753510/aeac0e51382d/jamanetwopen-e2142725-g002.jpg

相似文献

1
Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic.估计美国大流行期间疫苗接种运动后的 COVID-19 感染、住院和死亡人数。
JAMA Netw Open. 2022 Jan 4;5(1):e2142725. doi: 10.1001/jamanetworkopen.2021.42725.
2
COVID19 meets the antivaccine movement.新冠病毒与反疫苗运动相遇。
Microbes Infect. 2020 May-Jun;22(4-5):162-164. doi: 10.1016/j.micinf.2020.05.010. Epub 2020 May 19.
3
Can COVID-19 vaccines stop the pandemic?新冠疫苗能阻止疫情大流行吗？
Hong Kong Med J. 2021 Apr;27(2):84-85. doi: 10.12809/hkmj215116.
4
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.在以色列全国范围内使用辉瑞-生物科技公司的 BNT162b2 mRNA COVID-19 疫苗进行疫苗接种运动，以预防感染、住院和死亡：一项回顾性监测研究。
Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1. Epub 2021 Sep 22.
5
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
6
Signals of hope: gauging the impact of a rapid national vaccination campaign.希望的信号：评估全国快速疫苗接种运动的影响。
Nat Rev Immunol. 2021 Apr;21(4):198-199. doi: 10.1038/s41577-021-00531-0.
7
How many COVID deaths are acceptable in a post-pandemic world?在疫情后的世界里，多少新冠死亡人数是可以接受的？
Nature. 2021 May;593(7859):326-327. doi: 10.1038/d41586-021-01220-7.
8
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.COVID-19 病例和住院情况按 COVID-19 疫苗接种状况和既往 COVID-19 诊断情况划分-加利福尼亚州和纽约州，2021 年 5 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
9
Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.利用血清流行率调查估计美国 SARS-CoV-2 感染、有症状感染、住院和死亡人数。
JAMA Netw Open. 2021 Jan 4;4(1):e2033706. doi: 10.1001/jamanetworkopen.2020.33706.
10
Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021.儿童和青少年因 COVID-19 住院情况 - COVID-NET，14 个州，2020 年 3 月 1 日至 2021 年 8 月 14 日。
MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1255-1260. doi: 10.15585/mmwr.mm7036e2.

引用本文的文献

1
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.评估2023 - 2024年新冠病毒疫苗接种在美国避免的与新冠病毒疾病（COVID - 19）相关的住院、重症监护病房（ICU）收治及院内死亡情况：一种基于条件概率、因果推断和乘数的方法。
Vaccine. 2025 Mar 7;49:126808. doi: 10.1016/j.vaccine.2025.126808. Epub 2025 Jan 30.
2
Causal Estimands for Analyses of Averted and Avertible Outcomes due to Infectious Disease Interventions.传染病干预措施所避免和可避免结果分析的因果估计量
Epidemiology. 2025 May 1;36(3):363-373. doi: 10.1097/EDE.0000000000001839. Epub 2025 Jan 24.
3

本文引用的文献

1
Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis.无症状 SARS-CoV-2 感染：系统评价和荟萃分析。
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34). doi: 10.1073/pnas.2109229118.
2
Can the USA return to pre-COVID-19 normal by July 4?美国能在7月4日前恢复到新冠疫情前的正常状态吗？
Lancet Infect Dis. 2021 Aug;21(8):1073-1074. doi: 10.1016/S1473-3099(21)00324-8. Epub 2021 Jun 2.
3
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.单剂 Ad26.COV2.S 疫苗预防新冠病毒的安全性和有效性。
COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.
纽约市疫情早期住院的以少数族裔为主的队列中新冠病毒疫苗的接种情况。
Vaccine. 2024 Dec 2;42(26):126260. doi: 10.1016/j.vaccine.2024.126260. Epub 2024 Sep 11.
4
SARS-CoV-2 infection and vaccination in patients with pituitary diseases: the experience of a Brazilian reference center.垂体疾病患者的新型冠状病毒感染与疫苗接种：巴西一家参考中心的经验
Pituitary. 2024 Dec;27(6):992-999. doi: 10.1007/s11102-024-01456-2. Epub 2024 Sep 9.
5
Consequences of COVID-19 Vaccine Hesitancy Among Healthcare Providers During the First 10 Months of Vaccine Availability: Scoping Review.COVID-19 疫苗犹豫对医疗保健提供者的影响：疫苗可获得的头 10 个月的范围综述。
Can J Nurs Res. 2024 Sep;56(3):204-224. doi: 10.1177/08445621241251711. Epub 2024 May 2.
6
A population level study on the determinants of COVID-19 vaccination rates at the U.S. county level.一项关于美国县级层面 COVID-19 疫苗接种率决定因素的人群水平研究。
Sci Rep. 2024 Feb 21;14(1):4277. doi: 10.1038/s41598-024-54441-x.
7
Covid19Vaxplorer: A free, online, user-friendly COVID-19 vaccine allocation comparison tool.Covid19Vaxplorer：一款免费、在线且用户友好的新冠疫苗分配比较工具。
PLOS Glob Public Health. 2024 Jan 22;4(1):e0002136. doi: 10.1371/journal.pgph.0002136. eCollection 2024.
8
Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.预测 SARS-CoV-2 导致的健康结果的模型，包括疫苗接种的效果：系统评价。
Syst Rev. 2024 Jan 16;13(1):30. doi: 10.1186/s13643-023-02411-1.
9
Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases.半剂量的ChAdOx1 nCoV-19疫苗在减少中度和重度新冠肺炎病例方面与全剂量相当。
IJID Reg. 2023 Sep 30;9:88-94. doi: 10.1016/j.ijregi.2023.09.007. eCollection 2023 Dec.
10
A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran.定量评估疫苗推出速度和覆盖率对降低死亡率的影响：来自伊朗 COVID-19 疫情前 2 年的见解。
BMC Med. 2023 Nov 13;21(1):429. doi: 10.1186/s12916-023-03127-8.
N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21.
4
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.